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Abstract	
The	development	of	alloreactivity	following	stem	cell	transplantation	(SCT)	in	HLA	matched	donor-
recipient	pairs	(DRP)	appears	to	be	random.	Minor	histocompatibility	antigens	(mHA)	are	critical	in	graft	
versus	host	disease	(GVHD)	pathophysiology	however,	the	quantitative	relationship	between	GVHD	and	
the	magnitude	of	mHA	in	donor-recipient	pairs	(DRP)	is	not	known.	Whole	exome	sequencing	(WES)	was	
performed	on	27	HLA	matched	related	donors	(MRD),	&	50	unrelated	(URD),	to	identify	nonsynonymous	
single	nucleotide	polymorphisms	(SNPs)	with	an	average	2,490	SNPs	were	identified	in	MRD,	and	4,287	
in	URD	DRP	(p<0.01).	The	resulting	peptide	antigens	that	may	be	presented	on	the	relevant	HLA	class	I	
molecules	in	each	DRP	were	derived	in	silico	(NetMHCpan	ver2.0)	and	the	tissue	expression	of	proteins	
these	were	derived	from	determined	(GTex).	MRD	DRP	had	an	average	3,626	HLA-alloreactive	peptide	
(AP)	complexes	with	an	IC50	of	<500	nM	and	URD,	had	5,386	(p<0.01).	To	simulate	a	donor	cytotoxic	T	
cell	response	to	these	AP,	the	array	of	HLA-AP	complexes	in	each	patient	was	considered	as	an	operator	
matrix	modifying	a	hypothetical	cytotoxic	T	cell	clonal	vector	matrix	in	which	each	responding	T	cell	
clone’s	proliferation	is	quantified	by	the	logistic	equation	of	growth.	The	simulated	steady	state	T	cell	
clonal	response	to	the	AP-HLA	complexes	in	each	DRP,	accounted	for	the	HLA	binding	affinity	and	
expression	of	each	AP.	The	resulting	simulated	organ-specific	alloreactive	T	cell	clonal	growth	revealed	
marked	variability	between	different	DRP.	The	sum	of	all	T	cell	clones	for	common	GVHD	target	organs	
was:	MRD,	median	188,821	cytotoxic	T	cells	at	steady	state	(n=26),	MUD,	201,176	(n=35),	single	locus	
HLA-mismatch	MUD:	56,229	(n=10).	Despite	an	estimated,	uniform	set	of	constants	used	in	the	model	
for	all	DRP,	and	a	heterogeneously	treated	group	of	patients,	overall	there	was	a	non-significant	trend	
for	higher	organ	specific	T	cell	counts	in	patients	with	GVHD	compared	to	those	with	none,	with	weak	
associations	observed	for	GVHD	of	the	liver.	In	conclusion,	exome	wide	sequence	differences	and	the	
variable	AP	binding	affinity	to	the	HLA	in	each	DRP	yields	a	large	range	of	possible	alloreactive	donor	T	
cell	responses	possibly	explaining	the	random	nature	of	alloimmune	responses	observed	in	clinical	
practice.	Incorporating	other	quantitative	sources	of	T	cell	response	variability	may	allow	simulations	
like	this	to	accurately	model	alloreactivity	in	SCT	in	the	future.				 	
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Introduction	
Over	the	last	four	decades	there	have	been	substantial	strides	made	in	the	optimizing	the	clinical	
outcomes	following	allogeneic	stem	cell	transplantation	(SCT).	Nevertheless,	outcomes	such	as	relapse	
and	graft	versus	host	disease	(GVHD)	remain	difficult	to	predict	in	individuals	because	of	the	variability	
observed	in	the	incidence	of	alloreactivity	following	HLA	matched	SCT	using	conventional	GVHD	
prophylaxis	regimens.	[1,	2,	3,	4,	5,	6,	7]	To	an	extent	this	is	also	true	of	HLA	mismatched	transplantation	
using	novel	GVHD	prophylaxis	regimens.	[8,	9]	Considering	that	disease	responses	in	allogeneic	SCT	are	
often	linked	to	the	development	of	GVHD,	it	is	important	to	understand	the	biological	basis	of	the	
randomness	observed	in	the	incidence	of	alloreactivity.	[10]	Relapse	and	GVHD	are	a	function	of	donor-
derived	immune	reconstitution,	which	shows	many	characteristics	of	a	dynamical	system,	such	as	
logistic	growth	kinetics	and	power	law	distribution	of	clonal	frequencies.	[11,	12,	13,	14,	15]	This	implies	
that	if	the	quantitative	basis	of	randomness	in	clinical	outcomes	can	be	understood	in	terms	of	donor	
derived	immune	reconstitution,	it	will	become	possible	to	modify	the	system	to	optimize	clinical	
outcomes.				
In	HLA	Matched	SCT,	recipient	antigens,	specifically,	minor	histocompatibility	antigens	(mHA)	are	
presented	on	the	HLA	molecules.	These	mHA	released	following	conditioning	or	infection	induced-tissue	
injury	are	taken	up	by	antigen	presenting	cells	and	presented	to	non-tolerant	donor	T	cells,	which	in	the	
event	of	antigen	recognition,	proliferate	and	home	back	to	the	target	tissue	initiating	a	graft	vs.	host	
response.	Quantifying	the	mHA	disparity	in	a	SCT	donor-recipient-pair	(DRP)	may	therefore	allow	
exploration	of	the	origin	of	the	stochastic	nature	of	alloreactivity.	It	has	been	shown	that	both	the	
magnitude	and	rate	of	recovery	of	donor-derived	T	cells	influence	the	likelihood	of	relapse,	GVHD	and	
survival.	[11]	This	indicates	that	T	cell	responses	to	recipient	antigens	may	be	modeled	as	dynamical	
systems,	with	quantitative	rules	that	govern	repertoire	evolution	under	normal	circumstances	and	
following	transplantation.	T	cell	repertoire	is	exceedingly	complex,	it	is	very	likely	that	the	antigenic	
background	will	be	equally	as	complex.	Therefore	the	antigenic	background	in	a	DRP	may	be	similarly	
described	mathematically	as	a	component	of	this	dynamical	system.		These	antigenic	differences	in	a	
given	transplant	DRP	may	be	partially	determined	using	whole	exome	sequencing	(WES)	of	SCT	donor	
and	recipient	DNA.	WES	has	demonstrated	that	there	is	a	large	library	of	non-synonymous	single	
nucleotide	polymorphisms	(nsSNP),	and	an	equally	large	array	of	nsSNP-derived-peptides	which	would	
have	different	amino	acid	sequences	in	each	DRP.	[16,	17]	Of	these	nsSNPs,	those	present	in	the	
recipient	but	absent	in	the	donor	will	in	theory,	yield	an	array	of	immunogenic	recipient	peptides	which	
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may	trigger	donor	T	cell	activation	and	proliferation,	in	other	words,	an	array	of	mHA	bound	to	the	
‘matched’	HLA	in	the	DRP.	In	aggregate	these	polymorphisms	constitute	an	alloreactivity	potential	
between	the	specific	donors	and	recipients.	In	studies	done	to	date,	large	magnitude	of	this	
alloreactivity	potential	has	been	observed	in	all	the	HLA	matched	DRP	examined.	When	a	dynamical	T	
cell	response	to	this	mHA	array	is	calculated	marked	variation	in	the	simulated	T	cell	response	is	
observed,	suggesting	that	the	number	and	the	HLA	binding	affinity	of	the	mHA	may	determine	that	
likelihood	of	alloreactivity.	[18]	Similar	observation	reporting	association	of	polymorphisms	in	the	
peptide	regions	of	HLA	class	I	molecules	support	the	premise	outlined	above.	[19]		
Nevertheless,	alloreactivity	is	a	complex	clinical	state,	where	patients	may	have	variable	manifestations	
of	GVHD	impacting	different	organ	systems	to	varying	extent.	In	this	paper	the	impact	of	tissue-specific-
expression	of	the	proteins	that	the	mHA	are	derived	from	in	different	individuals	is	examined	to	
measure	its	variability	between	unique	transplant	DRP.	This	is	done	using	a	T	cell	vector-mHA	operator	
system	previously	developed	[18]	with	a	uniform	set	of	conditions	employed	to	simulate	a	hypothetical	
CD8+	T	cell	response	to	the	in	silico	derived	mHA-HLA	class	I	array	in	77	HLA	matched	SCT	DRP.				
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Methods.		
Patients	
Whole	exome	sequencing	(WES)	was	performed	on	previously	cryopreserved	DNA	obtained	from	donors	
and	recipients	of	allogeneic	SCT.	Permission	for	this	retrospective	study	was	obtained	from	the	Virginia	
Commonwealth	University’s	institutional	review	board,	and	patient’s	who	underwent	transplantation	
between	2010	and	2014	were	retrospectively	selected	for	this	analysis.	Patients	had	undergone	either	
8/8	(n=67)	or	7/8	(n=10)	HLA-A,	B,	C	and	DRB1	matched	related	(MRD;	n=27)	or	unrelated	(MUD;	n=50)	
or	haploidentical	(n=1)	SCT	according	to	institutional	standards	at	Virginia	Commonwealth	University	
(VCU)	(Supplementary	Table	1).	HLA	matching	had	been	performed	using	high	resolution	typing	for	the	
unrelated	donor	SCT	recipients;	and	intermediate	resolution	typing	for	class	I,	and	high	resolution	typing	
for	class	II	antigens	for	related	donor	recipients.	A	variety	of	different	conditioning	and	GVHD	
prophylaxis	regimens	were	used	in	the	patients.	HLA	class	I	typing	information	for	the	donor	and	
recipient	was	acquired	from	the	clinical	data	base.		
Whole	Exome	Sequencing		
Nextera	Rapid	Capture	Expanded	Exome	Kit	was	used	to	extract	exomic	regions	from	the	DNA	samples,	
which	were	then	multiplexed	and	sequenced	on	an	Illumina	HiSeq	2500	to	achieve	an	average	coverage	
of	~90X	per	sample.	2X100	bp	sequencing	reads	were	then	aligned	to	the	human	reference	genome	
using	BWA	aligner.	Duplicate	read	alignments	were	detected	and	removed	using	Picard	tools.	Single	
nucleotide	polymorphisms	(SNPs)	in	both	the	donor	and	recipients’	exomes	were	determined	using	
GATK	HaplotypeCaller	walker.	GATK	best	practices	were	then	implemented	to	filter	and	recalibrate	the	
SNPs;	and	store	them	in	variant	call	file	(VCF)	format.	To	identify	SNPs	unique	to	the	recipient	and	
absent	in	the	donor	the	results	from	the	GATK	pipeline	in	VCF	format	were	then	parsed	through	the	in-
house	TraCS	(Transplant	pair	Comparison	System)	set	of	perl	scripts.	TraCS	traverses	through	the	
genotypes	of	the	called	SNPs,	systematically	excluding	identical	SNPs	or	editing	them	to	align	with	the	
graft-versus-host	(GVH)	direction	thereby	generating	a	new	VCF	with	SNPs	for	a	particular	DRP	in	the	
GVH	direction	(SNP	present	in	the	recipient,	absent	in	the	donor).		
The	SNPs	in	this	VCF	are	then	annotated	either	as	synonymous	or	non-synonymous	using	Annovar.	The	
corresponding	amino	acid	polymorphisms	along	with	flanking	regions	of	each	protein	are	then	extracted	
using	Annovar	to	build	peptide	libraries	of	17-mers	for	each	DRP,	with	the	SNP	encoded	AA	occupying	
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the	central	position.	This	library	is	further	expanded	by	sliding	a	9-mer	window	over	each	17-mer	such	
that	the	polymorphic	amino-acid	position	changes	in	each	9-mer.	The	HLA	class	I	binding	affinity	and	
IC50	values,	which	quantify	the	interactions	between	all	these	9-mers	for	each	DRP	and	all	six	HLA	class	I	
donor	molecules	(HLA-A,	B	and	C),	NetHMCpan	version	2.8	was	run	iteratively	in	parallel	mode	on	a	
linux	cluster	using	custom	python	scripts.	Parsing	the	NetMHCPan	output,	unique	peptide-HLA	
combinations	present	in	the	recipient	but	not	in	the	donor,	i.e.,	possessing	a	GVHD	vector,	were	
identified	and	organized	in	order	of	declining	mHA-HLA	affinity.	IC50	(nM)	indicated	the	amount	of	
peptide	required	to	displace	50%	of	intended	or	standard	peptides	specific	to	a	given	HLA.	Binding	
affinity	is	inversely	related	to	IC50,	such	that,	smaller	the	IC50	value,	the	stronger	is	the	affinity.	The	
variant	alloreactive	peptides	with	a	cutoff	value	of	IC50	≤500	are	included	in	the	analyses	presented	
here.		
The	Genotype-Tissue	Expression	(GTEx)	portal	V6	has	publicly	available	expression	level	information	
(Reads/kilobase	of	transcripts/million	mapped	reads,	RPKM	values;	http://www.gtexportal.org/home/)	
for	a	variety	of	human	tissues	over	a	large	number	of	genes.	As	we	know	the	genes	from	where	the	
peptides	in	our	DRP	peptide	library	are	originating	from,	we	are	able	to	parse	in	the	RPKM	values	from	
the	GTEx	portal	for	that	gene	across	the	whole	array	of	tissues	of	interest,	namely,	skin,	lung,	salivary	
gland,	esophagus,	small	intestine,	stomach,	colon	and	liver.	In	the	DRP	where	a	male	recipient	had	been	
transplanted	from	a	female	donor	(n=17),	full	length	available	sequences	of	all	proteins	encoded	by	the	
Y	chromosome	were	curated	from	NCBI	and	other	resources	(see	supplementary	material).	These	
sequences	were	then	computationally	split	into	9-mer	peptides	and	their	respective	binding	affinities	
and	IC50	values	for	the	relevant	donor	HLA	antigens	were	determined	in	silico	using	the	NetMHCpan	
software	as	described	earlier.	These	peptides	were	then	appended	to	the	corresponding	DRPs	peptide	
library	for	all	subsequent	analyses.			
Computational	Methods:	Dynamical	System	Modeling	Of	T	Cell	Response	To	Putative	mHA	
It	was	postulated	that	the	immune	effectors	and	their	antigenic	targets	constitute	a	dynamical	system,	
i.e.	an	iterating	physical	system,	where	the	variable	being	studied	evolves	over	time,	and	the	state	of	
any	variable	at	any	given	time	(t),	is	predicated	on	all	the	preceding	states	of	the	systems.	A	system	
demonstrating	logistic	growth	of	immune	effectors	may	be	described	by	the	general	equation	
𝑑𝑁 𝑑𝑡 =𝑟𝑁! 𝐾 − 𝑁!𝐾 	
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Here,	dN/dt	is	the	instantaneous	rate	of	change	of	the	cell	population	at	time	t,	when	the	population	Nt	
has	an	intrinsic	growth	rate,	r	and	a	maximum	size,	K.	This	logistic	dynamical	system	constitutes	a	
system	of	repeated	calculations,	where	the	output	of	the	equation	for	each	iteration	gives	the	
population	Nt,	as	a	function	of	time,	and	becomes	the	input	variable	(argument)	for	the	next	calculation	
Nt+1.	This	system	behaves	in	a	non-linear	fashion,	demonstrating	sigmoid	population	growth	constrained	
by	feedback.	[18,	20,	21]	
If	SCT	is	considered	as	a	system	of	interacting	donor	T	cell	clones	and	recipient	antigens,	immune	
reconstitution	following	SCT	may	be	modeled	mathematically.	Each	T	cell	clone	responding	to	its	target	
antigen	will	proliferate,	conforming	to	the	iterating	logistic	equation	of	the	general	form		
𝑁!= !(!!!!!!)(!!!")!!																				[1]	
In	this	equation:	Nt,	is	the	T	cell	count	at	time	t	following	transplant	(modeled	as	iterations);	Nt-1 
represents	the	T	cell	count	in	the	previous	iteration;	K	is	the	T	cell	count	under	steady	state	conditions	
reached	after	several	iterations,	and	represents	the	maximum	T	cell	count	the	system	would	support	
(carrying	capacity);	r,	is	the	growth	rate	of	the	population;	and	t	is	the	number	of	iterations	that	the	
population	has	gone	through	(representing	time).	T	cell	population,	Nt,	at	time,	t	following	SCT,	is	a	
function	of	the	T	cell	population	Nt-1,	at	an	earlier	time	point,	t-1.	This	in	turn	will	depend	on	the	T	cell	
population	at	the	outset	of	transplant	N0,	and	the	intrinsic	T	cell	proliferative	capacity	(growth	rate)	r	
governing	the	growth,	such	that		
	 	 			N0 [r] Nt-1 [r] Nt [r] K 
In	this	model,	the	final	steady	state	population	of	all	the	T	cell	clones	(n)	( 𝐾!! ),	and	its	clonal	repertoire	
may	be	studied	for	associations	with	clinical	outcomes.		
Matrices	To	Model	The	T	Cell	Clonal	Repertoire:	Vector	Spaces	And	Operators	
To	apply	the	logistic	equation	to	describe	the	evolution	of	all	the	individual	T	cell	clones	present	in	an	
individual	at	a	given	time,	in	other	words,	to	simulate	the	evolution	of	the	T	cell	clonal	repertoire	
responding	to	the	entire	WES	derived	mHA-HLA	library	for	an	individual	DRP,	matrices	are	utilized.	T	cell	
clones	present	in	an	individual	may	be	considered	as	a	set	of	individual	vectors	in	the	immune	phase	
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space	of	that	individual.	The	descriptor,	vector,	in	this	instance	is	used	to	describe	the	entire	set	of	T	
cells,	with	the	individual	T	cell	clones	representing	components	of	this	vector	[22].	In	this	vector,	T	cell	
clonality	represents	direction	(since	it	determines	antigen	specificity)	and	T	cell	clonal	frequency,	the	
magnitude	of	individual	vector	components.	The	sum	of	these	vectors	will	represent	the	overall	T	cell	
vector	and	its	direction,	in	this	simulation,	recipient-directed	alloreactivity.	The	T	cell	vectors	may	take	a	
number	of	different	configurations	in	an	individual,	and	the	entire	range	of	possible	vector	
configurations	will	constitute	the	immune	phase	space	for	that	individual.	The	T	cell	vector	may	be	
represented	mathematically	as	a	single	row	matrix,	with	T	cell	clonal	frequencies	TC1, TC2, TC3 …. TCn.	
This	T	cell	clonal	matrix	may	be	represented	by	the	term,	𝜈!"#.		The	frequency	of	each	TC	is	a	natural	
number,	and	the	direction,	its	reactivity,	represented	by	the	clonality.	Phase	space	will	then	describe	all	
the	potential	T	cell	clonal	frequency	combinations	possible,	within	a	specific	antigenic	background,	with	
all	the	potential	directions	of	the	T	cell	reactivity.	In	the	case	reported	here,	the	vectors	are	all	in	the	
direction	of	graft	vs.	host	alloreactivity,	since	they	proliferate	after	encountering	mHA-HLA.	In	contrast,	
the	infused	T	cell	clonal	repertoire	will	represent	a	steady	state	T	cell	clonal	frequency	distribution	in	the	
normal	donor,	presumably	made	up	of	mostly	self-tolerant,	pathogen	specific	T	cells,	and	without	any	
auto-reactive	T	cells.	For	the	computations	reported	here,	each	T	cell	clone	has	a	N0	value	of	1,	and	is	
alloreactive.	
The	T	cells	infused	with	the	transplant	encounter	a	new	set	of	antigens	(both	recipient	and	pathogen).	
These	antigens	presented	by	the	recipient	(or	donor-derived)	antigen	presenting	cells	constitute	an	
operator,	a	matrix	of	targets	in	response	to	which	the	donor	T	cells	may	proliferate	[23].	This	operator	
changes	the	magnitude	and	direction	(clonal	dominance)	of	the	infused	T	cell	repertoire,	as	individual	T	
cell	clones	in	the	donor	product	grow	or	shrink	in	the	new	HLA-antigen	milieu,	transforming	the	T	cell	
vector.	The	putative	mHA	making	up	the	alloreactivity	potential	constitute	a	matrix,	which	may	be	
termed	an	alloreactivity	potential	operator,	𝕄!"#.	This	operator	will	consist	of	the	binding	affinity	of	
the	unique	variant	peptide-HLA	complexes	likely	to	be	encountered	by	donor	T	cells	in	an	individual	
recipient.	Following	SCT,	the	donor	T	cell	clonal	frequency	shifts	according	to	the	specificity	of	the	TCR	
and	the	abundance	and	reactivity	of	the	corresponding	antigen.	This	corresponds	to	the	operator	
modifying	the	original	donor	T	cell	vector,	𝜈!"#	as	the	system	goes	through	successive	iterations	to	a	
new	recipient	T	cell	vector,	𝜈!"#,	according	to	the	following	relationship	𝜈!"#  ⋅  𝕄!"# =  𝑣!"#  																				 	 				[2]	
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Applying	the	Logistic	Growth	Equations	to	Vector-Operator	Systems	
A	central	assumption	in	this	model	is	that	the	steady	state	TC	clonal	frequency	(K)	of	specific	TCR	
bearing	clones,	and	their	growth	rates	(r),	are	proportional	to	the	binding	affinity	of	their	target	mHA-
HLA	complexes.	This	is	approximately	represented	by	the	reciprocal	of	the	IC50	(test	peptide	
concentration	in	nM	required	to	displace	a	standard	peptide	from	the	HLA	molecule	in	question)	for	that	
specific	complex.	This	is	because	the	strength	of	the	binding	affinity	will	increase	the	likelihood	of	T	cell-
APC	interactions	occurring,	thus	influencing	the	driving	the	rate	of	this	interaction.	While	each	TCR	may	
recognize	another	mHA-HLA	complex	with	equal	or	lesser	affinity,	for	the	sake	of	simplicity,	an	
assumption	of	non-recognition	of	other	mHA-HLA	complexes	was	made	for	this	model.	This	makes	it	
possible	to	specify	an	identity	matrix,	Matrix	A,	with	unique	mHA-HLA	complexes	for	a	SCT-DRP	and	the	
corresponding	TCR,	where	TCRx	recognizes	mHAx-HLA	(1)	and	not	others	(0).	In	addition	to	the	
assumption	that	there	is	a	first	signal	of	TCR	recognition,	a	second	signal	immune	responsiveness	is	
assumed	in	this	matrix.		
Matrix	I.	Effect	of	alloreactivity	operator	𝕄!"#	on	T	cell	vector	𝜈!"#.	Successive	iterations	(t)	modify	the	
vector	to	𝜈!"#.	In	this	simplified	model,	mHAx-HLA	only	effects	TCx	and	so	on.	Matrix	below	represents	a	
single	iteration	t.		
SCT	 𝕄!"#	
𝜈!"#	↓ t	𝜈!"# 	
	 mHA1	HLA	 mHA2	HLA	 mHA3	HLA	 mHAn	HLA	
TC1	 1	 0	 0	 0	
TC2	 0	 1	 0	 0	
TC3	 0	 0	 1	 0	
TCn	 0	 0	 0	 1	
The	alloreactivity	matrix	modifies	the	donor	T	cell	clonal	vector	infused	with	an	allotransplant,	mapping	
it	to	the	recipient	T	cell	vector,	as	the	T	cell	clones	with	unique	TCR	encounter	the	corresponding	mHA-
HLA	complexes	they	proliferate	conforming	to	the	logistic	equation	[1].	In	the	logistic	equation	K	for	
each	T	cell	clone	will	be	proportional	to	the	approximate	binding	affinity	(1 𝐼𝐶50)	of	the	corresponding	
mHA-HLA	complex	(𝐾!/!"!").	The	parameter	r	is	a	function	of	the	binding	affinity	(by	increasing	the	TCR-
mHA-HLA	interaction	time)	and	the	intrinsic	T	cell	proliferation	capacity.		Equation	1	must	therefore	be	
modified	for	unique	TC clone	TCx,	responding	to	mHAx-HLA,	as	follows:	
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𝑁! !"#= !!/!"!"!"#$(!! !"!" !"#$!!!!! !"#)(!!!" ! !"!"!"#$ )!!																	[3]	
This	general	equation	gives	instantaneous	T	cell	counts	in	response	to	antigens	presented,	regardless	of	
tissue	distribution.	In	the	alloreactivity,	vector-operator	identity	matrix,	the	values	1	or	0	in	each	cell	are	
multiplied	by	the	product	of	equation	3	for	each	T	cell	clone.	This	is	depicted	in	Matrix	II.	
Matrix	II.	Matrix	illustrating	a	single	iteration	of	the	alloreactivity	operator	𝕄!"#	on	T	cell	vector	𝜈!!".	
Each	cell	in	the	matrix	calculates	the	value	of	TCx	in	response	to	mHAx-HLA,	final	repertoire	is	
determined	by	solving	the	matrix.		
SCT	 𝕄!"#	
𝜈!"#	↓ t	𝜈!"#	
	 mHA1	HLA	
mHA2	
HLA	
mHA3	
HLA	
mHAx	HLA	
TC1	 𝑁! !"!= 𝐾!/!"!"!"# !(𝐾! !"!" !"#! − 𝑁!!! !"!)(𝑒!!" ! !"!"!"#! ) + 1	 0	 0	 0	
TC2	 0	 NtTC2	 0	 0	
TC3	 0	 0	 NtTC3	 0	
TCx	 0	 0	 0	 NtTCx	
The	T	cell	response	to	each	mHA-HLA	complex	is	determined	over	time,	t,	by	iterating	the	system	of	
matrix-equations.	In	this	alloreactivity	matrix,	the	IC50	of	all	the	alloreactive	peptides	with	a	GVH	
direction	(present	in	recipient,	but	absent	in	donor)	constitutes	the	operator;	the	sum	of	n	T	cell	clones	𝑇𝐶 !! ,	at	each	time	point	will	represent	the	magnitude	of	the	vector	𝜈!"#  at	that	time	t.	In	this	system,	
when	considering	the	effect	on	infused	donor	T	cell	vector,	depending	on	antigen	affinity,	T	cell	clones	
present	in	abundance	may	be	down-regulated	if	antigen	is	not	encountered.	On	the	other	hand,	clones	
present	at	a	low	frequency	may	expand	upon	encountering	antigen,	transforming	the	vector	over	time	
from	the	original	infused	T	cell	vector.	In	summary,	the	alloreactivity	operator	determines	the	change	in	
donor	T	cell	vectors,	following	transplantation,	in	an	iterative	fashion	transforming	it	to	a	new	
configuration,	over	time	t,	based	on	the	mHA-HLA	complexes	encountered	in	the	recipient	and	their	
affinity	distribution	(and	antigen	abundance,	vide	infra).	Therefore	post-SCT	immune	reconstitution	may	
be	considered	as	a	process	in	which	T	cell	clonal	frequency	vectors	are	iteratively	multiplied	by	the	
minor	histocompatibility	antigen	matrix	operator	and	this	results	in	transformation	of	the	vector	over	
time	to	either	a	GVHD-prone	alloreactive	or	to	a	tolerant,	pathogen-directed	vector.	This	may	be	
visualized	as	thousands	of	T	cell	clones	interacting	with	antigen	presenting	cells,	an	example	of	an	
interacting	dynamical	system.	[11]		
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Competition	between	T	Cell	Clonal	Populations		
Each	of	the	T	cell	clones	is	behaving	like	a	unique	population,	therefore	competition	with	other	T	cell	
clones	in	the	set	of	all	T	cell	clones	must	be	accounted	for	in	the	logistic	equation	to	determine	the	
magnitude	of	the	unique	clonal	frequencies	as	the	model	iterates	simulating	T	cell	clonal	growth	over	
time.	This	may	be	done	using	the	Lotka-Volterra	model	for	competing	populations,	which	accounts	for	
the	impact	of	population	growth	of	multiple	coexisting	populations	[18,	24,	25].	This	is	accomplished	by	
modifying	the	expression	Nt-1	in	equation	3	for	each	clone,	by	taking	the	sum	of	Nt-1 for	all	the	other	
competing	T	cell	populations	when	calculating	Nt	for	each	clone.	Each	clone’s	Nt-1	is	weighted	by	a	
correction	factor	α for	its	interaction	with	the	T	cell	clone	being	examined.	Given	the	central	role	for	the	
target	mHA-HLA	complex’s	IC50	in	determining	the	T	cell	frequency	for	each	clone,	α	for	each	clone	is	
calculated	by	dividing	the	IC50	of	the	competing	T	cell	clone	with	the	test	clone	(note	the	use	of	IC50	
instead	of	1/IC50).	This	implies	that	T	cell	clones	recognizing	mHA-HLA	complexes	with	a	higher	binding	
affinity	will	have	a	disproportionately	higher	impact	on	the	growth	of	T	cell	clones	binding	less	avid	
mHA-HLA	complexes	and	vice	versa.	The	resulting	square	matrix,	Matrix	III,	will	have	1	on	the	diagonal,	
and	values	<1	above	the	diagonal	and	>1	below	it.				
Matrix	III.	Matrix	illustrating	the	relative	effect	of	antigen	binding	affinity	on	the	T	cell	clonal	interaction	
between	different	clones.	Successive	cells	in	each	row	of	the	matrix	calculate	the	effect	of	TCi	on	T	cell	
being	studied,	TCx.	This	generates	a	weighting	factor,	α,	which	modulates	the	impact	of	population	of	TCi	
on	the	growth	of	TCx.				
	 TC1	 TC2	 TC3	 TCn	
TC1	 IC501/IC501	 IC501/IC502	 IC501/IC503	 IC501/IC50n	
TC2	 IC502/IC501	 IC502/IC502	 IC502/IC503	 IC502/IC50n	
TC3	 IC503/IC501	 IC502/IC503	 IC503/IC503	 IC503/IC50n	
TCn	 IC50n/IC501	 IC50n/IC503	 IC50n/IC503	 IC50n/IC50n	
To	account	for	n	competing	T	cell	populations,	equation	3	will	be	modified	as	follows	
𝑁! !"#= !!/!"!"!"#$!! !"!" !"#$! !!!! !"#.!!!! (!!!" ! !"!"!"#$ )!!	 	 [3.1]	
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Where	for	the	T	cell	clone	x,	Nt	depends	on	the	sum	of	the	n	T	cell	clonal	frequencies	at	the	previous	
iteration,	with	the	α	of	each	T	cell	clone	i,	with	respect	to	the	T	cell	clone	x,	modifying	the	effect	of	the	
frequency	of	the	ith	clone	on	TCx.	By	contrast,	the	parameter	r	can	have	either	positive	or	negative	
values	depending	on	whether	the	ambient	cytokine	milieu,	either	stimulates	(-r)	or	suppresses	(+r)	
growth.		
The	direction	of	the	T	cell	clones	will	be	determined	by	antigen	specificity,	i.e.	whether	their	TCR	
recognize	the	recipient’s	mHA-HLA	(are	alloreactive)	or	not	(are	tolerant),	such	as	pathogen	directed	T	
cell	clones.	For	example,	a	tolerant,	non-autoreactive	set	of	T	cell	clones	(donor	vector,	𝜈!"#)	may	be	
transformed	to	a	predominantly	alloreactive	set	of	T	cell	clones	(𝜈!!"),	after	interacting	with	the	mHA-
HLA	complex,	alloreactivity	operator	encountered	in	the	recipient	(𝕄!"#).	
Accounting	for	tissue	expression	of	proteins	
The	peptides	discussed	in	the	afore	mentioned	derivation	are	generated	from	proteins	expressed	in	
target	tissues,	as	such	the	level	of	protein	expression	will	determine	the	magnitude	of	the	peptide	
specific	T	cell	response.	The	higher	the	protein	expression,	the	more	peptide	molecules	and	the	greater	
the	HLA	presentation	with	an	ability	to	stimulate	a	larger	T	cell	response	(clonal	frequency).	Therefore	
the	parameter	K	in	the	above	equations	may	be	modeled	as	a	multiple	of	the	level	of	protein	
expression.	The	tissue	expression	of	proteins	is	estimated	by	RNA	sequencing	techniques,	and	is	
measured	in	either	transcripts	per	million	(TPM)	or	reads	per	kilobase	of	transcript	per	million	mapped	
reads	(RPKM).	The	values	available	from	the	public	data	base	GTEx,	range	from	0	to	>104	and	constitute	
a	coefficient	in	the	definition	of	K.	This	Modifies	Equation	3.1,	
𝑁! !"#= (!"#$!.!)!/!"!"!"#$(!"#$!.!)! !"!" !"#$! !!!! !"#.!!!! (!!!" ! !"!"!"#$ )!! 						 	 ….		[3.2]	
	
In	equation	3.2,	the	tissue	expression	of	the	protein	from	which	the	target	peptide, mHAx	is	derived	is	
incorporated	as	a	K	multiplier	when	calculating	a	tissue-specific	T	cell	response.	Thus	tissue-specific	
alloreactivity	potentials	may	be	simulated	for	each	of	the	relevant	GVHD	target	tissues,	by	substituting	
equation	3.2	into	Matrix	II.				
In	applying	this	model	to	exome	sequence	derived,	alloreactive-peptide-HLA	binding	patient	data	an	
IC50	cutoff	value	of	≤500	nM,	and	an	RPKM	value	of	≥1	were	chosen	to	study	the	differences	between	
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patients.	The	T	cell	repertoire	simulations	were	then	run	in	MATLAB	(Mathworks	Inc.,	Natick,	MA),	
utilizing	the	above	model	(See	Supplementary	Mathematical	Methods	and	Program).		
The	sum	of	all	T	cell	clones	 𝑇𝐶 !! for	each	specific	organ	of	interest	and	the	grand	total	of	the	organs	
studied	(termed	sum	of	all	clones)	were	used	to	represent	the	T	cell	vector	magnitude	of	the	alloreactive	
T	cells	at	steady	state	for	each	patient.		
Statistical	Methods		
Estimated	T	cell	counts	are	summarized	per	organ	and	in	total	with	means	and	standard	deviations,	both	
overall	and	by	GVHD	classification.	In	addition,	variability	measures	of	estimated	T	cell	counts	across	
organs	within	individuals	(standard	deviation,	minimum,	maximum,	and	range)	are	summarized	in	the	
same	manner.	The	estimated	T	cell	counts	and	variability	measures	are	compared	between	GVHD	and	
Donor	Type	groups	using	the	Wilcoxon	rank	sum	test.	Cox	proportional	hazards	models	are	used	to	
examine	associations	between	both	the	estimated	T	cell	counts	and	variability	measures	with	patient	
outcomes	(GVHD,	survival,	relapse	and	relapse-free	survival).	The	MEANS,	NPAR1WAY	and	PHREG	
procedures	in	the	SAS	statistical	software	program	(version	9.4,	Cary,	NC,	USA)	are	used	for	summaries	
and	analyses.	All	estimated	T	cell	counts	are	divided	by	1000	to	simplify	the	presentation	of	results.		
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Results.		
Exome	sequencing	
Cryopreserved	DNA	samples	from	78	donors	and	recipients	of	allogeneic	SCT	were	sequenced,	
demographic	details	of	the	patients	are	given	in	supplementary	table	1.	Whole	exome	sequencing	
revealed	a	significantly	larger	number	of	SNPs,	both	synonymous	as	well	as	non-synonymous	in	
recipients	of	MUD	SCT	when	compared	with	MRD	recipients	(Table	1).	Further,	a	majority	of	these	SNPs	
were	nonconservative,	i.e.	likely	to	substitute	an	AA	with	different	physico-chemical	properties,	so	liable	
to	bring	about	a	conformational	change.	In	patients	who	either	did	or	did	not	develop	GVHD,	an	average	
of	2456	and	2474	nsSNPs	were	identified	in	recipients	of	MRD,	while	the	corresponding	numbers	for	
MUD	recipients	were	4536	and	3845	nsSNPs.	In	the	one	haploidentical	transplant	recipient,	there	were	
3231	ns	SNPs.	Notably,	the	transition/transversion	ratio	in	the	WES	data	was	as	expected	between	2.1	
and	2.5	for	the	entire	data	set	(Supplementary	Fig	1).	
In	silico	derivation	of	mHA-HLA	complexes	from	exome	variation	
The	nsSNPGVH	data	arrays	then	served	as	the	basis	to	computationally	determine	peptide	sequences.	For	
each	variant	amino	acid	(AA)	resulting	from	a	nsSNPGVH,	the	flanking	8	AA	on	either	side	were	
determined	and	the	resulting	nonamers,	with	the	variant	AA	occupying	all	nine	positions	derived	for	
each	variant	AA.	The	binding	affinity	of	each	of	these	peptides	was	determined	to	the	HLA	class	I	(A,	B	
and	C)	molecules	in	each	pair.	This	yielded	a	large	array	of	unique	peptide-HLA	complexes,	in	other	
words	putative	or	potential	minor	histocompatibility	antigens	(mHA)	in	each	individual;	once	again	a	
significantly	larger	number	of	peptides	of	both	presented	and	strongly	bound,	were	observed	in	MUD	
recipients	when	compared	with	MRD	(Table	1).	A	similar	number	of	peptides	with	an	IC50	<500nM,	
3826	and	3406	pmHA,	were	recorded	in	MRD	patients	either	with	or	without	GVHD	respectively;	
corresponding	numbers	were	895	and	778	mHA	with	an	IC50	<50nM	for	those	patient	groups.	For	the	
MUD	SCT	pairs	(n=50),	the	corresponding	numbers	were	5672	and	4876	pmHA	with	an	IC50	<500	nM	
and	1210	and	1071	with	an	IC50	<50	nM	in	patients	with	or	without	GVHD.	Notably	these	numbers	do	
not	include	the	Y	chromosome	derived	peptides	presented	by	the	class	1	HLA	molecules	in	male	
recipients	of	female	donors.	The	haploidentical	donor	had	2448	peptides	with	an	IC50	of	<500	nM	out	of	
a	total	57957	peptides;	of	these	484	were	strongly	bound,	when	using	the	recipient	HLA	for	performing	
the	calculation.	
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Simulating	recipient	tissue	specific	donor	T	cell	responses	
Following	determination	of	the	mHA	with	various	binding	affinity	distributions,	the	T	cell	responses	to	
these	antigens	were	simulated	using	the	T	cell	vector-	alloreactivity	operator	model	[Equations	2	&	3.2].	
The	underlying	conditions	used	in	these	calculations	were	as	follows:	for	each	mHA	there	was	a	single	T	
cell	present	at	the	first	iteration,	i.e.	Nt	=	1	at	t	=	1.	The	K	in	equation	3.2	was	set	at	1000,000	cells	(note:	
this	value	substitutes	for	organ	mass,	lympho-vascular	supply	etc.	without	accounting	for	differences	
between	organs),	and	r	was	set	at	1.5	for	all	the	simulations	(note:	in	vivo	this	may	vary	with	state	of	
inflammation).	All	the	mHA	were	included	in	the	simulations	with	competition,	and	included	Y	
chromosome	encoded	peptides	which	bound	respective	HLA	in	the	male	recipients	of	female	donors.	
The	program	accounted	for	both	IC50	and	tissue	expression	measured	as	RPKM	for	each	mHA	to	
simulate	donor	T	cell	responses	to	organs	of	interest,	with	skin,	salivary	gland,	esophagus,	stomach,	
small	intestine,	colon,	liver,	spleen,	blood,	blood	vessel,	lung	included	in	the	analysis.	Individual	clonal	
growth	was	variable	depending	on	the	HLA	binding	affinity	of	the	peptide,	as	well	as	the	tissue	
expression	of	protein,	however	the	relationship	was	not	linear	(Figure	2).	T	cell	clones	responding	to	low	
expression/low	binding	affinity	were	suppressed	and	had	negative	values	and	recovered	over	time	
(iterations	of	the	system).	The	T	cell	clonal	growth	for	each	organ’s	alloreactive	peptides	was	summed	to	
give	the	simulated	alloreactive	T	cell	count	for	each	organ	in	each	individual.	The	average	value	for	each	
organ	at	steady	state	(average	of	the	iteration	#	401-500)	was	determined	and	is	shown	for	each	patient	
(Figure	3A)	and	depicts	the	magnitude	of	organ-specific	alloreactive	T	cell	response	that	may	be	seen	in	
different	DRP,	accounting	for	their	HLA	types	and	exome	sequence	variation.	The	simulated	organ-
specific	T	cell	counts	responding	to	the	alloreactivity	operator	demonstrate	marked	variability	in	both	
HLA	matched	related	and	unrelated	donors,	both	between	different	DRP	(Figure	3B)	as	well	as	within	
DRP	(Figure	3C).	This	is	true	for	individual	organ	simulations,	as	well	as	the	sum	of	these	simulations	
(Figure	3D),	which	reflects	the	variation	in	the	organ	specific	T	cell	responses.	
When	the	sum	of	all	organ	specific	T	cell	clones	(Σ	TC)	was	examined	in	different	donor	types,	no	
significant	differences	were	observed	in	any	of	the	categories	examined;	MRD:	median	188,821	ΣTC	at	
steady	state	(n=26)	vs.	MUD:	201,176	(n=35)	vs.	HLA	mm	donor:	56,229	(n=10).	However,	while	the	
differences	were	not	statistically	significant	between	these	retrospectively	chosen	groups,	there	was	a	
trend	supporting	quantitative	differences	between	different	donor	types.	Estimated	T	cell	counts	are	
summarized	by	donor	type	in	Supplementary	Table	2,	where	for	every	organ	(and	overall)	the	mean	
expected	T	cell	counts	and	estimated	variabilities	are	larger	in	patients	with	unrelated	donors	than	they	
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are	in	patients	with	matched	related	donors,	however	none	of	these	differences	were	significant	(all	p-
values	>	0.3),	most	likely	due	to	the	high	variability	of	these	estimates.	No	significant	differences	were	
observed	when	other	biological	features	such	as	gender	mismatch	in	the	DRP	(F	to	M:	270,613	(n=17),	M	
to	F:	135,064	(n=14)	vs.	gender	match	(F	to	F:	180,574	(n=16),	M	to	M:	114,932	(n=26),	and	difference	in	
races,	(AA	to	AA:	113,245	(n=13),	vs.	C	to	C:	215,337	(n=47),	vs.	race	mm:	57,938	(n=6))	were	studied.		
This	corroborates	well	with	the	relatively	weak	effect	of	these	biological	differences	in	the	development	
of	GVHD	in	the	setting	of	HLA	matching.	[26,	27]		However	the	small	sample	size	and	heterogeneity	of	
our	group	in	terms	of	conditioning	and	GVHD	prophylaxis	may	also	contribute	to	the	variability	observed	
in	clinical	outcomes.			
Clinical	association	of	tissue-specific	alloreactivity	potential		
The	simulated	T	cell	counts	are	summarized	in	Supplementary	Table	3,	where	for	every	organ	(and	
overall)	the	mean	simulated	T	cell	counts	were	larger	in	patients	who	eventually	developed	any	form	of	
GVHD,	than	they	were	in	patients	who	did	not	develop	GVHD,	though	none	of	these	differences	were	
significant.	As	can	be	seen	in	Supplementary	Table	4,	that	while	none	of	the	organ-specific	simulated	T	
cell	counts	were	associated	with	GVHD	(all	p-values	between	0.05	and	0.15),	the	variability	(standard	
deviation)	among	organ-specific	T	cell	estimates	in	individuals	is	significantly	associated	(HR	=	1.08,	95%	
CI:	1.01,	1.15,	p	=	0.0275)	with	GVHD,	as	was	the	maximum	organ-specific	T	cell	estimate	(HR	=	1.01,	
95%	CI:	1.00,	1.02,	p-value	=	0.0462)	and	the	range	between	the	maximum	and	minimum	organ-specific	
t-cell	counts	(HR	=	1.02,	95%	CI:	1.00,	1.05,	p-value	=	0.0276).	These	results	imply	that	increased	
variability	of	T	cell	counts	among	organs	are	associated	with	a	minimal	increase	in	the	risk	of	GVHD.	
Similar	analyses	for	survival,	relapse	and	relapse-free	survival	were	not	significant	for	any	of	the	organ-
specific	T	cell	counts	or	the	variability	measures	(all	p-values	>	0.5).	While	these	are	weak	associations	at	
best,	it	is	noteworthy	that	despite	an	estimated,	uniform	set	of	constants	used	in	the	model	for	all	DRP,	
heterogeneously	treated	group	of	patients,	overall	there	was	a	trend	for	higher	organ	specific	T	cell	
counts	in	patients	with	GVHD	compared	to	those	with	none.	
Cox	proportional	hazards	models	for	acute	and	chronic	GVHD	are	presented	in	Supplementary	Table	5,	
and	demonstrated	no	significant	associations	between	expected	t-cell	counts	and	variability	measures	
with	acute	GVHD	(all	p-values	>	0.05).	For	chronic	GVHD,	only	the	expected	T	cell	counts	from	the	liver	
were	significantly	associated,	with	a	slight	positive	relationship	(HR	=	1.01,	95%	CI:	1.00,	1.03,	p-value	=	
0.0411).	The	standard	deviation	among	organ-specific	t-cell	estimates	is	significantly	(p	=	0.0404)	and	
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positively	associated	(HR	=	1.08,	95%	CI:	1.01,	1.16)	with	GVHD,	as	was	the	range	between	the	maximum	
and	minimum	organ-specific	T	cell	counts	(HR	=	1.03,	95%	CI:	1.01,	1.05,	p-value	=	0.0266).	These	results	
imply	that	increased	variability	of	t-cell	counts	among	organs	are	associated	with	slight	increases	in	the	
risk	of	chronic	GVHD.		
There	were	no	associations	between	organ-specific	expected	T	cell	counts	and	the	organ-specific	
occurrence	of	acute	GVHD	(all	p-values	>	0.5).	Only	expected	T	cell	counts	in	salivary	glands	was	
significantly	and	positively	associated	with	oral	chronic	GVHD	(HR	=	1.02,	95%	CI:	1.01,	1.04,	p	=	0.0131);	
all	other	organ-specific	expected	t-cell	counts	were	not	associated	with	organ-specific	chronic	GVHD	(p-
values	>	0.09).	
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Discussion.	
Alloreactivity	following	SCT	is	a	complex	disorder	dependent	on	a	number	of	factors	such	as	degree	of	
HLA	matching,	[28,	29,	30]	intensity	of	immunosuppression	[31,	32,	33]	and	the	graft	source/T	cell	
composition	of	the	graft.	[34,	35]	However,	even	within	uniformly	HLA	matched	and	immunosuppressed	
patients	with	similar	disease	biology,	outcomes	remain	variable	and	subject	to	laws	of	probability.	In	this	
paper	the	magnitude	of	difference	in	putative	alloantigen	presentation	between	SCT	DRP	is	explored,	
accounting	for	the	HLA	make	up	and	protein	coding	differences	between	individual	donors	and	
recipient.	Marked	variation	in	the	likelihood	of	alloantigen	presentation	is	observed	in	the	simple	
mathematical	model	utilized.	Further	despite	the	limited	nature	of	the	model	used,	a	trend	supporting	
association	of	the	alloreactive	simulations	with	clinical	GVHD	is	observed.		
Logically,	the	binding	affinity	and	tissue	expression	of	the	antigens	are	critical	parameters	when	
assessing	the	T	cell	response	to	these	antigens.	In	this	paper	findings	of	an	earlier	model	are	extended	to	
simulate	T	cell	responses	to	the	entire	array	of	alloantigens	that	the	donor	T	cells	may	encounter	in	a	
recipient	to	determine	tissue	specific	alloreactivity	potential.	Similar	to	the	previous	study,	the	findings	
reported	herein	demonstrate	a	very	large	degree	of	variability	between	the	simulated	T	cell	responses	
to	antigens	expressed	in	specific	organs	between	unique	pairs.	Furthermore,	while,	the	association	
between	clinical	GVHD	and	the	simulated	T	cell	responses	is	not	established,	there	are	intriguing	
associations	observed	which	represent	a	new	area	of	investigation	which	might	yield	interesting	results	
in	the	future.	
The	inability	to	identify	strong	clinical	association	between	the	magnitude	of	the	simulated	T	cell	
response	to	mHA	array	in	a	DRP	and	GVHD,	may	be	explained	by,	(a)	uniform	simulation	conditions	
applied	in	the	model,	despite	a	heterogeneously	treated	patient	cohort,	with	limited	numbers	in	each	
group,	(b)	only	9-mer	oligo	peptides	bound	to	HLA	class	I	considered	in	the	simulations,	and	those	too	
without	any	post	translational	modification	(phosphorylation,	glycosylation)	and	protein	cleavage	site	
information	incorporated.	Beyond	these	obvious	considerations	there	are	other	important	
considerations	that	needs	to	be	factored	in.	Logic	would	dictate	that	when	proteins	are	cleaved,	there	
will	be	a	host	of	peptides	generated	for	antigen	presentation,	both	alloreactive,	such	as	the	ones	
reported	here,	as	well	as	non-alloreactive	peptides	which	will	also	bind	HLA	with	varying	levels	of	
affinity,	as	the	alloreactive	peptides	do.	Furthermore	these	peptides	will	likely	be	far	more	numerous	
than	the	alloreactive	ones,	and	may	constitute	a	significant	competitive	barrier	to	the	presentation	of	
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alloreactive	peptides.	This	may	be	modeled	numerically	using	the	notion	of	combinatorial	probability.	
[36,	37]	In	other	words,	if	there	are	n	total	peptides	which	might	be	presented	on	k	HLA	molecule	there	
are,	
	 !!!!!! = !!!!!!!! !!! ! 		
possible	combinations	of	peptides	which	might	be	presented	by	these	HLA	molecules,	including	
duplication	of	peptides	and	without	regard	to	order	of	peptides	presented.	For	example,	if	10	peptides	
are	to	be	presented	by	4	HLA	molecules	the	total	number	of	possible	peptide-HLA	combinations	will	be,	!"! = 715.	Now,	of	these,	if	3	peptides	are	alloreactive	(mHA),	the	probability	of	a	favorable	outcome	
(NO	GVHD)	will	be	enhanced	if	the	other	7	non-alloreactive	peptides	are	presented,	the	number	of	
possible	combinations	allowing	that	will	be	 !"! 	=	210.	Therefore	the	probability	of	having	a	peptide	
combination	presented	by	one	of	the	four	HLA	molecules,	which	will	not	include	an	alloreactive	peptide	
in	this	mix	of	3/10	alloreactive	peptides,	will	be	approximately	!"!!"! =  0.293	
This	means	that	the	remaining	~70%	of	the	peptide-HLA	combinations	will	contain	one	or	more	
alloreactive	peptides,	if	this	combination	of	alloreactive	and	non-alloreactive	peptide	combinations	were	
to	be	presented.	Depending	on	the	binding	affinity	of	the	peptides,	and	the	potential	of	the	alloreactive	
peptide	to	stimulate	a	T	cell	response,	and	the	presence	of	a	T	cell	clone	recognizing	that	specific	
peptide	HLA	combination,	alloreactivity	may	or	may	not	be	triggered.	In	real	life	however	the	number	of	
non-alloreactive	peptides	is	likely	high	resulting	in	a	smaller	ratio	of	alloreactive	peptides	being	
presented.	Expression	levels	of	HLA	molecules	(k	in	the	above	equations)	have	been	shown	to	impact	
alloreactivity	in,	supporting	this	quantitative	reasoning.	[38,	39]	Nevertheless	this	quantitative	
consideration	adds	an	important	variable	to	determining	the	likelihood	of	alloreactivity	developing;	i.e.	
the	variability	in	the	HLA	binding	affinity	of	the	many	non-alloreactive	peptides	(not	accounted	for	in	the	
analysis	presented	in	this	paper).	Further	variability	in	this	system	is	introduced	by	the	relative	
abundance	of	each	protein	from	which	the	peptides	are	derived.	This	too	will	modify	the	likelihood	of	
peptide	binding	to	HLA,	due	to	competition.	This	discussion	demonstrates	that	while	dynamical	systems	
modeling	reproduces	T	cell	patterns	seen	in	patients,	randomness	of	the	exome	mutations,	and	
subsequent	peptide-HLA	interactions	makes	the	development	of	alloreactivity	a	stochastic,	dynamical	
process.		This	means	that	while	patterns	of	reactive	immune	responses	may	be	mathematically	
described,	each	of	these	patterns	is	associated	with	a	certain	probability	of	occurring	and	thus	bringing	
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about	the	associated	clinical	outcome.	In	other	words,	HLA	matched	patients	with	a	higher	simulated	T	
cell	count	will	likely	be	at	greater	risk	of	GVHD	under	certain	uniform	conditions	of	immunosuppression	
and	vice	versa.			
Another	source	of	difference	between	an	idealized	simulation	and	the	‘real	world’	will	be	the	interaction	
between	APC	and	T	cells.	Both	the	cell	populations	proliferate	in	response	to	inflammatory	stimuli,	with	
the	APC	proliferation	driving	T	cell	growth.	This	interaction	too	may	be	modeled,	using	the	matrix	based	
vector	operator	model.	The	results	reported	above	are	based	on	the	notion	that	the	APC	matrix	
operator	(MAPO)	has	a	constant	effect	of	the	donor	T	cell	vector,	in	other	words	antigen	presentation	is	a	
constant	function	of	time,	however	in	life	this	is	not	the	case.	APC	themselves	respond	to	inflammatory	
signals	and	as	previously	demonstrated	follow	logistic	growth	and	decline	after	stem	cell	
transplantation,	consequently	antigen	presentation	follows	a	crescendo-decrescendo	course	over	time	
(particularly	with	infections).	[40,	41]	This	model	may	be	built	into	this	system	of	vector	operator	
immune	response	modeling.	In	this	instance	consider	the	scenario;	tissue	injury	following	conditioning	
therapy	ensues,	following	which	there	is	uptake	of	recipient	antigens	by	the	transplanted	APC	
(presumably	of	donor	origin)	proliferating	in	response	to	the	cytokines	released	as	a	consequence	of	the	
insult.	The	proliferating	APC	take	up	antigen	and	present	the	mHA	(and	non-mHA)	and	migrate	to	the	
regional	lymph	nodes.	As	these	monocyte	populations	arrive	in	the	regional	nodes,	the	T	cells	
corresponding	to	the	mHA	start	proliferating	and	migrate	out	of	the	lymph	node	and	homing	to	the	
target	tissue,	where	they	now	induce	further	inflammatory	injury,	further	expanding	the	APC	
proliferation,	until	the	APC	population	reaches	a	steady	state.	Once	the	tissue	damage	is	complete	(or	
infection	resolved),	the	APC	will	decline	and	a	steady	state	memory	T	cell	complement	left	behind.	This	
is	a	positive	feed	back	loop	which	‘self	regulates’	as	steady	state	values	are	reached	for	the	APC	
population,	with	an	eventually	decline	in	the	antigen	presentation	(as	pathogen	numbers	decline,	or	
maximal	tissue	injury	runs	its	course).	Similar	to	T	cell	clonal	proliferation,	APC	proliferation	may	be	
described	by	equation	1.	The	progressive	rise	and	fall	in	the	number	of	APC,	(and	consequent	waxing	
and	waning	antigen	presentation	over	time)	may	then	be	described	as	a	vector,	and	its	impact	in	T	cell	
population	be	recorded	by	taking	the	dot	product	of	this	and	the	T	cell	vector,	in	other	words	
multiplying	each	iteration	of	the	T	cell	vector	as	it	transforms.	The	logistic	variable	describing	the	impact	
of	APC	growth	and	decline	on	T	cell	clonal	proliferation	is	given	by	the	expression,	𝜈!"#= 1 − N! !"#𝐾!"# 𝑡 + 1	
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This	variable	is	at	its	highest	value,	2,	in	the	beginning	of	the	reaction	(Nt	APC/KAPC	approaches	0)	but	as	
the	reaction	proceeds	over	time	t,	it	approaches	1,	as	Nt	APC	approaches	K	APC.	Here	1	represents	the	
binary	(0/1)	condition	of	T	cell	clone	specificity	for	target	mHA	in	MAPO,	in	real	world	terms	the	steady	
state	capability	of	the	T	cell	to	proliferate	when	encountering	the	relevant	antigen.	Assuming	that	an	
independent	𝜈!"# 	exists	for	each	antigen	in	the	MAPO,	the	effect	of	APC	growth	and	subsequent	mHA	
presentation	may	be	obtained	by	the	dot	product	of	the	two	vectors,	𝜈!"# 	and	𝜈!"#.	In	other	words,	
multiplying	each	iteration	of	the	T	cell	vector	with	each	iteration	of	this	APC	vector	(the	operation	of	
multiplying	2	column	matrices),	transforms	the	donor	T	cell	vector,	
𝜈!"#′	=	𝜈!"# 	.	𝜈!"# 	.	𝑐𝑜𝑠𝜃	
This	equation	implies	that	in	the	beginning	of	an	inflammatory	response	there	is	a	positive	feedback	
response	from	proliferating	APC,	which	amplifies	the	T	cell	response	𝜈!"#′;	eventually	both	decay	to	a	
steady	state	level.	The	angle	θ	between	the	two	vectors	is	0 °	(cos	0	=	1)	because	they	have	the	same	
direction,	in	other	words	the	TCR	recognize	the	mHA-HLA	complex	being	presented	by	the	APC.	This	
effect	of	𝜈!"# 	on	𝜈!"#  can	be	applied	to	the	entire	T	cell	repertoire	and	is	shown	in	Figure	4A	for	a	
single	T	cell	clone	and	may	be	generalized	to	the	whole	repertoire	(Figure	4B).	As	can	be	seen	these	
graphs	recapitulate	the	T	cell	response	amplification	commonly	observed	in	response	to	antigen	
stimulation,	[40,	41,	42]	and	can	be	depicted	in	the	model	illustrated	in	Figure	4C.	In	practice,	this	
interaction	depending	on	the	presence	or	absence	of	inflammation	in	the	tissues	being	studied,	will	
significantly	modify	the	alloreactivity	operator	and	lead	to	variability	in	T	cell	proliferation	observed.	The	
weak	associations	of	the	T	cell	simulations	with	the	clinical	findings	reported	in	this	paper,	may	
therefore	be	explained	by	absence	of	information	regarding	the	overall	inflammatory	state	in	each	DRP.	
This	can	certainly	be	modeled	in	the	future	iterations	of	such	work.		
Another	source	of	clinical	variability	that	is	not	accounted	for	in	this	model	is	the	make	up	of	the	graft	
both	in	terms	of	effector,	as	well	as	regulatory	T	cells	(Treg).	While	the	notion	of	absence	of	antigen	
directed	clonal	T	cells	impacting	the	predictive	power	of	any	such	model	is	straight	forward,	the	effect	of	
regulatory	immune	cell	populations	such	as	Treg	requires	some	calculation	to	understand.	Treg	
recognize	self-antigens	and	secrete	anti-inflammatory	cytokines	(IL-4,	IL-10)	in	response,	diminishing	the	
proliferation	of	the	antigen	directed	CD8+	effector	T	cells.	[43]	This	may	be	easily	accounted	for	in	this	
model	by	considering	that	the	growth	parameter	r	(given	the	uniform	value	of	-1.5	in	this	analysis)	
represents	the	proliferative	effect	of	the	cytokine	milieu.	In	this	instance	the	more	negative	its	value	
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(induced	by	pro-inflammatory	cytokines),	the	larger	the	growth	promoting	effect,	and	the	less	negative	
or	positive	the	value	(anti-inflammatory	cytokine	effect)	the	more	growth	will	be	impeded	or	stopped,	
as	can	be	seen	in	Figure	5,	where	a	change	in	the	magnitude	of	r	produces	dramatic	decline	in	the	T	cell	
growth	curves.	Once	again	these	effects	are	not	accounted	for	in	the	model	presented	here	but	may	be	
easily	included.	Nevertheless,	the	robustness	of	the	vector	operator	model	of	quantifying	T	cell	response	
and	its	eventual	clinical	utility	are	indicated	by	its	robustness	in	quantifying	a	variety	of	immune	
phenomenon	noted	above.			
Current	clinical	practice	is	to	identify	the	donors	is	based	on	the	degree	of	major	histocompatibility	locus	
matching.	Based	on	this,	immunosuppressive	regimens	are	chosen;	unrelated	donor	transplant	
recipients	frequently	receive	ATG	in	addition	to	the	standard	calcinuerin	inhibitor	+	methotrexate,	
haploidentical	transplant	recipients	receive	post	transplant	cyclophosphamide	and	so	on.	In	the	absence	
of	early	GVHD	onset,	immunosuppression	intensity	is	gradually	reduced	and	eventually	withdrawn	over	
a	predetermined	period	of	time,	usually	spanning	four	to	six	months,	depending	on	the	relapse	risk	of	
the	underlying	malignancy.	Dynamical	system	modeling	of	immune	reconstitution,	based	on	whole	
exome	sequencing	data	from	donors	and	recipients	may	enable	the	development	of	patient	specific	
immunosuppressive	regimens	post	transplant,	by	more	precisely	calibrating	the	GVHD	risk	that	unique	
donors	might	pose	to	that	patient.	Given	the	advances	in	next	generation	sequencing,	as	well	as	
computing	technology	it	is	conceivable	that	in	time	patients	and	their	prospective	donors	will	have	their	
HLA	type	and	alloreactivity	potential	determined	by	whole	exome	sequencing.	A	donor	with	optimal	
alloreactivity	potential	will	be	identified	and	a	GVHD	prophylaxis	regimen	of	optimal	intensity	utilized	to	
achieve	maximal	likelihood	of	good	clinical	outcome.	In	so	doing,	dynamical	systems	understanding	of	
alloimmune	T	cell	responses	will	attenuate	the	unpredictability	that	the	current	largely	probability	based	
models	of	outcomes	prediction	expose	patients	to.	The	dynamical	systems	analysis	of	antigenic	variation	
also	explains	the	randomness	at	hand	in	human	immune	response	to	disease,	either	infectious	or	
neoplastic.	This	understanding	has	the	potential	to	impact	areas	of	investigation	beyond	transplant	
alloreactivity,	potentially	influencing	cancer	immunotherapy,	autoimmune	disease	and	infectious	
disease.		Randomness	within	the	dynamical	system	will	remain	a	problem	for	the	foreseeable	future,	but	
a	model	such	as	this	is	a	step	towards	gaining	a	quantitative	understanding	of	complex	immune	
responses.	
In	conclusion	this	model	partially	explains	why	immune	responses	are	seemingly	random	and	difficult	to	
accurately	predict,	akin	to	the	quantum	uncertainty	principle,	you	can	accurately	measure	either	a	
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particle’s	position	or	its	velocity,	never	both.		Similarly,	given	the	complexity	at	hand	in	immune	
responses,	we	will	not	be	able	to	precisely	quantify	the	likelihood	of	alloreactivity,	but	with	a	
quantitative	understanding	give	a	more	accurate	estimate	of	the	probability	distribution.	
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Figures.	
Figure	1.	TRaCS,	computational	algorithm	to	determine	tissue	specific	alloreactive	peptide	mHA.	
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Figure	2.	Individual	T	cell	clonal	growth	simulations	accounting	for	peptide-HLA	complex	binding	affinity	
and	protein	of	origin	RPKM.	Increased	T	cell	frequency	(Y-axis)	seen	if	the	protein	is	expressed	at	a	
higher	level.	IC50/RPKM	given	for	each	T	cell	clone.			
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Figure	3A.		Tissue	specific	simulated	alloreactive	T	cell	counts	in	recipients	of	MRD	(Black	line)	and	
unrelated	donors	(Blue	line).	These	values	represent	the	sum	of	the	entire	T	cell	vector	responding	to	
the	alloreactivity	operator	matrix	of	mHA-HLA	complexes	for	a	specific	organ,	including	the	negative	
values	
					
	
	
	
Figure	3B	&	3C.		Variation	in	the	simulated	alloreactive	T	cell	counts	observed	for	each	organ	examined	
between	patients	(3B)	and	within	patients	(3C).	Note	Log	scale	used	in	Figure	3B,	but	not	in	3C		(Y	axis	
truncated	at	130000).	
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3C.	
	
	
	
	
Figure	3D.		Cumulative,	simulated	alloreactive	T	cell	counts	in	recipients	of	MRD	(Black	line)	and	
unrelated	donors	(Blue	line)			
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Figure	4:	Alloreactivity	model.	Dot	product	of	APC	and	T	cell	vectors	recapitulates	familiar	antigen-
challenge	driven	T	cell	proliferation	response	curve.	A.	Single	T	cell	clone,	B.	Entire	repertoire.	C.	Model	
illustrating	the	interaction	between	APC	and	T	cells.		
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Figure	5.		Modeling	the	effect	of	Treg	on	effector	T	cell	growth:	in	the	red	curve	r	reduced	at	21st	
iteration	from	1	to	0.25;	T	cell	population	drops	but	then	recovers	slowly.	In	the	blue	curve	r	reduced	at	
25th	iteration	from	1	to	0.25	with	direction	reversal	(from	–	to	+),	signifying	anti-inflammatory	effect	
supersedes	pro-inflammatory	effect.	
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Tables.		
	
Table	1.	Exome	sequencing	and	peptide	results	by	donor	type	(n=77)	
	
		 Relateda	
(n=27)	
Unrelated	
(n=50)	
P-valueb	
Exome	sequencing	SNP	differences	
		Synonymous	 2,751	 4,821	 <0.01	
		Nonsynonymous	 2,490	 4,287	 <0.01	
		Conservative	 855	 1,476	 <0.01	
		Non-conservative	 1,635	 2,811	 <0.01	
HLA-Presented	Peptides	
		Peptides	 44,214	 77,025	 <0.01	
		Strong	Binders	 838	 1,160	 <0.01	
		Presented	Peptides	 3,626	 5,386	 <0.01	
		Percent	of	Strong	Binders	 1.9	 1.5	 0.03	
		Percent	of	Presented	Peptides	 8.3	 7.1	 0.05	
		Strong	Binders/Presented	Peptides	 22.6	 21.1	 0.08	
aExcludes	haploidentical	patient	
	 	 	bMean	values	compared	using	t-test	for	Equality	of	Means	
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Supplementary	Table	1.	Patient	characteristics,	excluding	haploidentical	DRP	
	
	 	
Age	Distribution 						<40 12	(16)
						40-59 43	(56)
						≥60 22	(29)
Donor 						MRD 26	(34)
						MUD 41	(53)
						MMRD 	1	(1)
						MMUD 9	(12)
Stem	Cell	Source 						Bone	Marrow 7	(9)
						Peripheral	Blood 70	(91)
Diagnosis 					Acute	lymphoid	leukemia 5	(6)
					Acute	myeloid	leukemia 29	(38)
					Chronic	lymphocytic	leukemia							
										and	lymphomas																																									 15	(19)
					Multiple	myeloma 4	(5)
					Myelodysplastic	syndromes																						 24	(31)
Conditioning	Regimen 						Anti-thymocyte	globulin	(ATG) 62	(81)
						Reduced	Intensity 46	(60)
												ATG/TBI 19	(25)
												Busulfan/Fludarabine 27	(35)
												Fludarabine/Melphalan 2	(77)
							Myeloablative 31	(40)
												Busulfan/Cyclophosphamide 17	(22)
												Cyclophosphamide/TBI 11	(14)
												Etoposide/TBI 1	(1)
GVHD	prophylaxis 						Cyclosporin	A/Methotrexate 16	(21)
						Cyclosporin	A/MMF 4	(5)
						Tacrolimus/Methotrexate 34	(44)
						Tacrolimus/MMF 23	(30)
GVHD,	Overall 						Acute,	Grades	I-II 20	(26)
						Acute,	Grades	III-IV 14	(18)
						Chronic 39	(51)
						Both,	Acute	+	Chronic 25	(32)
Supplemental	Table	1.												Patient	Characteristics,	n	(%)
Total	Transplants 77	(100)									
Patient	Age
										Male/Female 43	(55.8)/34	(44.2)
Gender
										Median	(range) 55.6	(21-73)					
																																																																																																																															Total
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Supplementary	Table	2:	Expected	T	cell	counts	per	donor	type	by	organ	(presented	in	1,000s	of	cells)	
Table	2	
	 MRD	(N=27)	 MUD	(N=45)	
	 Mean	 SD	 Mean	 SD	
Salivary	
Glands	
13.8	 14.9	 14.0	 20.0	
Colon	 18.4	 18.1	 20.2	 30.1	
Esophagus	 17.2	 17.8	 18.6	 28.1	
Small	
Intestines	
19.1	 20.3	 19.9	 25.7	
Stomach	 19.6	 19.5	 21.1	 27.3	
Liver	 18.4	 17.8	 22.6	 32.1	
Lung	 12.9	 12.9	 16.5	 25.6	
Skin	 19.3	 19.6	 20.9	 25.9	
Total	 138.8	 139.3	 154.8	 210.5	
Variance	Measures	
Standard	
Deviation	
3.6	 2.8	 4.7	 6.8	
Minimum	 22.7	 21.0	 27.3	 37.2	
Maximum	 11.8	 13.1	 12.8	 19.3	
Range	 10.9	 8.7	 14.4	 21.1	
Supplementary	Table	3.	Expected	T	cell	counts	by	organ	in	patients	with	and	without	GVHD	(presented	
in	1,000s	of	cells)	
Table	3	
	 Overall	(N	=	73)	 No	GVHD	(N=26)	 GVHD	(N=47)	
	 Mean	 SD	 Mean	 SD	 Mean	 SD	
Salivary	
Glands	
13.7	 18.1	 10.3	 11.9	 15.6	 20.6	
Colon	 19.3	 26.0	 15.3	 15.1	 21.4	 30.3	
Esophagus	 17.9	 24.5	 13.6	 14.4	 20.2	 28.5	
Small	
Intestines*	
19.3	 23.6	 14.4	 14.9	 22.1	 27.0	
Stomach	 20.3	 24.4	 15.5	 15.9	 22.9	 27.9	
Liver	 20.8	 27.5	 16.5	 15.9	 23.1	 32.1	
Lung	 15.0	 21.6	 11.4	 12.7	 16.9	 25.1	
Skin	 20.0	 23.6	 16.1	 16.9	 22.2	 26.5	
Total*	 146.7	 185.1	 113.1	 114.9	 165.7	 213.8	
*Indicates	sample	sizes	of	72	for	overall	and	46	for	GVHD	group	due	to	a	missing	value	
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Supplementary	Table	4.		Estimated	hazards	ratios,	95%	confidence	intervals	and	p-values	from	Cox-
proportional	hazards	models	of	t-cell	counts	and	GVHD	classification	
	
Table	4	
	 Hazard	Ratio*	 95%	CI	 p-value	
Salivary	Glands	 1.01	 0.99,	1.03	 0.1184	
Colon	 1.01	 0.99,	1.02	 0.1479	
Esophagus	 1.01	 0.99,	1.02	 0.1039	
Small	Intestines	 1.01	 0.99,	1.02	 0.0946	
Stomach	 1.01	 0.99,	1.02	 0.1055	
Liver	 1.01	 0.99,	1.02	 0.0546	
Lung	 1.01	 0.99,	1.02	 0.1248	
Skin	 1.01	 0.99,	1.02	 0.1442	
Total	 1.00	 0.99,	1.01	 0.0976	
Standard	
Deviation	
1.08	 1.01,	1.15	 0.0275	
Minimum	 1.01	 0.99,	1.03	 0.1049	
Maximum	 1.01	 1.00,	1.02	 0.0462	
Range	 1.02	 1.00,	1.05	 0.0276	
*Hazard	ratio	based	on	t-cell	counts	expressed	in	1,000s	
	
Supplementary	Table	5.	Estimated	hazards	ratios,	95%	confidence	intervals	and	p-values	from	Cox-
proportional	hazards	models	of	t-cell	counts	and	acute	and	chronic	GVHD	classification	
Table	5	
	 Acute	GVHD	 Chronic	GVHD	
	 Hazard	
Ratio*	
95%	CI	 p-value	 Hazard	
Ratio*	
95%	CI	 p-value	
Salivary	Glands	 1.01	 0.99,	1.03	 0.3806	 1.01	 0.99,	1.03	 0.1090	
Colon	 1.01	 0.99,	1.02	 0.4175	 1.01	 0.99,	1.02	 0.2394	
Esophagus	 1.01	 0.99,	1.02	 0.3379	 1.01	 0.99,	1.02	 0.1633	
Small	
Intestines	
1.01	 0.99,	1.02	 0.3880	 1.01	 0.99,	1.03	 0.0788	
Stomach	 1.01	 0.99,	1.02	 0.4788	 1.01	 0.99,	1.02	 0.1321	
Liver	 1.01	 0.99,	1.02	 0.1752	 1.01	 1.00,	1.03	 0.0411	
Lung	 1.01	 0.99,	1.02	 0.2664	 1.01	 0.99,	1.03	 0.2520	
Skin	 1.01	 0.99,	1.02	 0.3851	 1.01	 0.99,	1.02	 0.1732	
Total	 1.00	 0.99,	1.00	 0.3290	 1.00	 1.00,	1.00	 0.1202	
Standard	
Deviation	
1.07	 0.99,	1.15	 0.0618	 1.08	 1.01,	1.16	 0.0404	
Minimum	 1.01	 0.99,	1.03	 0.3492	 1.01	 0.99,	1.03	 0.1520	
Maximum	 1.01	 0.99,	1.02	 0.1526	 1.01	 0.99,	1.02	 0.0586	
Range	 1.02	 0.99,	1.05	 0.0539	 1.03	 1.01,	1.05	 0.0266	
*Hazard	ratio	based	on	t-cell	counts	expressed	in	1,000s	
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Supplementary	Figure	1:	Transition/transversion	ratio	for	the	WES	data	from	all	the	patients.		
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